These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14727937)

  • 1. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL
    Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
    Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
    Mousa SA; Kapil R; Mu DX
    Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2535-41. PubMed ID: 10521384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
    Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ
    Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
    Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.
    Seiffert D; Stern AM; Ebling W; Rossi RJ; Barrett YC; Wynn R; Hollis GF; He B; Kieras CJ; Pedicord DL; Cromley DA; Hua TA; Stein RB; Daly RN; Sferruzza A; Pieniaszek HJ; Billheimer JT
    Blood; 2003 Jan; 101(1):58-63. PubMed ID: 12393571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
    Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roxifiban. DMP 754, MK 0853, XJ 754.
    Drugs R D; 1999 May; 1(5):385-6. PubMed ID: 10566071
    [No Abstract]   [Full Text] [Related]  

  • 11. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
    Simpfendorfer C; Kottke-Marchant K; Lowrie M; Anders RJ; Burns DM; Miller DP; Cove CS; DeFranco AC; Ellis SG; Moliterno DJ; Raymond RE; Sutton JM; Topol EJ
    Circulation; 1997 Jul; 96(1):76-81. PubMed ID: 9236420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
    Akkerhuis KM; van Den Brand MJ; van Der Zwaan C; Peels HO; Suryapranata H; van Der Wieken LR; Stibbe J; Hoffmann J; Baardman T; Deckers JW; Simoons ML
    Heart; 2001 Apr; 85(4):444-50. PubMed ID: 11250974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
    Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
    Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
    Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
    Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
    Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
    Schulman SP; Goldschmidt-Clermont PJ; Topol EJ; Califf RM; Navetta FI; Willerson JT; Chandra NC; Guerci AD; Ferguson JJ; Harrington RA; Lincoff AM; Yakubov SJ; Bray PF; Bahr RD; Wolfe CL; Yock PG; Anderson HV; Nygaard TW; Mason SJ; Effron MB; Fatterpacker A; Raskin S; Smith J; Brashears L; Gottdiener P; du Mee C; Kitt MM; Gerstenblith G
    Circulation; 1996 Nov; 94(9):2083-9. PubMed ID: 8901655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist.
    Barrett YC; Ebling W; Pieniaszek H; Billheimer J; Seiffert D
    J Pharm Biomed Anal; 2007 Aug; 44(4):938-46. PubMed ID: 17485191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
    Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.